XML 46 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share (Tables)
9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following tables reconcile the components of the numerator and denominator included in the calculations of diluted income (loss) per share:

Three Months Ended September 30,

2016

2015
Numerator



Net income (loss) attributable to Inovio Pharmaceuticals, Inc.
$
(20,759,338
)

$
5,594,468

Reflect adjustment for decrease in fair value of warrant liability
(2,841
)

(616,477
)
Numerator for use in diluted income (loss) per share
$
(20,762,179
)

$
4,977,991





Denominator



Weighted average number of common shares outstanding
73,602,834


72,029,644

Effect of dilutive potential common shares
186,174


1,931,593

Denominator for use in diluted income (loss) per share
73,789,008


73,961,237


 
 
 
Net income (loss) per share, diluted
$
(0.28
)
 
$
0.07

 
Nine Months Ended September 30,
 
2016
 
2015
Numerator
 
 
 
Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(47,506,869
)
 
$
(11,235,561
)
Reflect adjustment for decrease in fair value of warrant liability

 
(928,978
)
Numerator for use in diluted loss per share
$
(47,506,869
)
 
$
(12,164,539
)
 
 
 
 
Denominator
 
 
 
Weighted average number of common shares outstanding
72,932,199

 
66,846,481

Effect of dilutive potential common shares

 
172,480

Denominator for use in diluted loss per share
72,932,199

 
67,018,961

 
 
 
 
Net loss per share, diluted
$
(0.65
)
 
$
(0.18
)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table summarizes potential common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three months ended September 30, 2016 and 2015:
 
 
Common Stock Equivalents
2016
 
2015
Options to purchase common stock
6,747,961

 
2,812,185

Restricted stock units
771,335

 

Convertible preferred stock
8,456

 
8,456

Total
7,527,752

 
2,820,641



The following table summarizes potential common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the nine months ended September 30, 2016 and 2015:
 
 
Common Stock Equivalents
2016
 
2015
Options to purchase common stock
6,747,961

 
5,875,211

Warrants to purchase common stock
284,091

 
580,904

Restricted stock units
771,335

 
230,000

Convertible preferred stock
8,456

 
8,456

Total
7,811,843

 
6,694,571